Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Recruiting

Phase 1

Phase 2

Ipatasertib & Megestrol AcetateTesting the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05538897

Conditions

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma

Metastatic Endometrial Endometrioid Adenocarcinoma

Recurrent Endometrial Endometrioid Adenocarcinoma

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Computed Tomography

Ipatasertib

Magnetic Resonance Imaging

Megestrol Acetate

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-19. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-28.